Clinical Trial Update: Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 exploratory trial assessing TG02 as monotherapy or with pembrolizumab in rectal cancer, terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• TG02

Snippet

Sponsor: Targovax ASA | Conditions: Rectal Cancer | Phase 1 | Status: TERMINATED | Results posted: 2022-01-26